Curaleaf (OTCMKTS:CURLF) Shares Up 4.8% – Should You Buy?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) shares rose 4.8% during trading on Friday . The stock traded as high as $9.81 and last traded at $9.81. 127,836 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 301,936 shares. The stock had previously closed at $9.36.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CURLF. Citigroup reaffirmed a “buy” rating on shares of Curaleaf in a report on Thursday, August 6th. Zacks Research upgraded shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Three investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to MarketBeat.com, Curaleaf presently has an average rating of “Strong Buy”.

Curaleaf Stock Performance

The stock’s 50-day moving average price is $8.22 and its 200-day moving average price is $7.96. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.52. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -74.30 and a beta of 1.56.

Curaleaf (OTCMKTS:CURLF) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.25. Curaleaf had a negative return on equity of 0.88% and a negative net margin of 2.62%.The business had revenue of $340.10 million for the quarter, compared to analysts’ expectations of $332.00 million. As a group, equities research analysts expect that Curaleaf Holdings, Inc. will post 0.01 earnings per share for the current year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.